POLYPLUS acquired by SARTORIUS

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component. This platform investment represents a highly synergistic and value-accretive maneuver for the acquirer, structurally designed to capture a significant share of the rapidly expanding cell and gene therapy market. The acquisition introduces vital technological complementarities, specifically bridging the target's pioneering expertise in viral vector production components with the acquirer’s established portfolio of cell culture media and advanced therapy essentials. By internalizing these capabilities, the acquirer strengthens its footprint in the United States while capitalizing on a sector characterized by high structural growth and accelerating pipeline developments. The financial parameters of the transaction underscore the premium nature of the target asset, driven by an intensively competitive environment wherein proactive industrial consolidators rapidly outpaced financial sponsors during the preemptive phase of the process. The deal delivers an exceptional exit profile for the incumbent sponsors, culminating in an impressive multiple on invested capital realized over the investment holding period.

In the past, the company had already been the subject of several LBOs, notably led by Archimed in 2016 and Warburg Pincus in 2020. This succession of buyouts highlights the strong attractiveness of the company's business model.